Open access
Jul 2026
TFAP2A links drug resistance to antitumor immunity
This work found that BRAF/MEK inhibitors significantly upregulate TFAP2A, and identifies TFAP2A as a shared driver of both targeted therapy resistance and immunosuppression, offering a one-stone-two-bird strategy to overcome drug resistance and elicit antitumor immunity.
Haiwei Mou, Veronika Yakovishina, Kristen M DeRosa et al.
· bioRxiv · 0 citations